| Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia. | |
| | |
MedLine Citation:
|
PMID: 12451477 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: Mylotarg, a humanized anti-CD33 antibody linked to an antitumor antibiotic, is approved for the treatment of patients with relapsed acute myeloid leukemia (AML). Topotecan and cytarabine (ara-C) is an effective anti-AML regimen. A pilot study of Mylotarg combined with topotecan and ara-C (MTA) was conducted in patients with refractory AML. METHODS: MTA consisted of Mylotarg 9 mg/m(2) intravenously (i.v.) over 2 h on day 1, ara-C 1 g/m(2) over 2 h i.v. on days 1 through 5, and topotecan 1.25 mg/m(2) by continuous infusion i.v. on days 1 through 5. RESULTS: A group of 17 patients (9 primary resistant, 8 relapsed) with AML or advanced myelodysplastic syndrome (MDS) received 20 courses of MTA. The median age of the patients was 55 years (20-70 years). Two patients (12%) achieved complete remission. The median overall survival was 8.2 weeks. Five patients (29%) developed grade 3/4 hepatic transaminitis, including one patient (6%) who died with hepatic venoocclusive disease. CONCLUSIONS: MTA was moderately effective and associated with significant toxicity in patients with refractory AML. |
| | |
Authors:
|
Jorge Cortes; Apostolia M Tsimberidou; Ricardo Alvarez; Deborah Thomas; Miloslav Beran; Hagop Kantarjian; Elihu Estey; Francis J Giles |
Related Documents
:
|
21810917 - Phase ii trial of dasatinib in patients with metastatic breast cancer using real-time p... 22252927 - Phase 2 results from radiation therapy oncology group study 0537: a phase 2/3 study com... 19380027 - Acute myeloid leukemia and diabetes insipidus with monosomy 7. 20087177 - Induction therapy in acute myeloid leukemia: intensifying and targeting the approach. 17670737 - Acute toxicity of irinotecan in the ex-vivo isolated perfused human lung model--high-do... 1433607 - The prognostic significance of vascular invasion in upper urinary tract transitional ce... |
Publication Detail:
|
Type: Clinical Trial; Journal Article Date: 2002-10-22 |
Journal Detail:
|
Title: Cancer chemotherapy and pharmacology Volume: 50 ISSN: 0344-5704 ISO Abbreviation: Cancer Chemother. Pharmacol. Publication Date: 2002 Dec |
Date Detail:
|
Created Date: 2002-11-26 Completed Date: 2003-02-13 Revised Date: 2006-04-24 |
Medline Journal Info:
|
Nlm Unique ID: 7806519 Medline TA: Cancer Chemother Pharmacol Country: Germany |
Other Details:
|
Languages: eng Pagination: 497-500 Citation Subset: IM |
Affiliation:
|
Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, Texas 77030, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acute Disease Adult Aged Aminoglycosides* Anti-Bacterial Agents / administration & dosage Antibodies, Monoclonal / administration & dosage Antigens, CD / immunology, metabolism Antigens, Differentiation, Myelomonocytic / immunology, metabolism Antineoplastic Combined Chemotherapy Protocols / adverse effects, therapeutic use* Cytarabine / administration & dosage Humans Infusions, Intravenous Leukemia, Myeloid / drug therapy*, metabolism Middle Aged Neoplasm Recurrence, Local / drug therapy*, metabolism Pilot Projects Remission Induction Salvage Therapy Survival Rate Topotecan / administration & dosage Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Aminoglycosides; 0/Anti-Bacterial Agents; 0/Antibodies, Monoclonal; 0/Antigens, CD; 0/Antigens, Differentiation, Myelomonocytic; 0/CD33 antigen; 0/gemtuzumab; 123948-87-8/Topotecan; 147-94-4/Cytarabine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Next Document: Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murin...